Eli Lilly share price boosted by obesity data for diabetes treatment

The Eli Lilly share has performed better than the broad S&P 500 index so far this year. After positive obesity data was announced for tirzepatide on Tuesday, the share got another boost.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030
by marketwire, translated by catherine brett

US-based Eli Lilly has had the wind in its sails on the stock market this week.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading